Newbury Pharmaceuticals AB (publ) (STO:NEWBRY)

Sweden flag Sweden · Delayed Price · Currency is SEK
1.135
-0.130 (-10.28%)
Jan 21, 2026, 2:48 PM CET
-67.76%
Market Cap38.45M
Revenue (ttm)36.23M
Net Income (ttm)-25.78M
Shares Out30.40M
EPS (ttm)n/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume266,414
Average Volume89,699
Open1.220
Previous Close1.265
Day's Range1.000 - 1.250
52-Week Range1.000 - 3.560
Beta1.24
RSI45.02
Earnings DateJan 21, 2026

About STO:NEWBRY

Newbury Pharmaceuticals AB (publ) operates as hybrid pharmaceutical company in Sweden and the Scandinavian market. The company offers oncology, rare diseases, neurology, and other treatment products. Newbury Pharmaceuticals AB (publ) was incorporated in 2020 and is based in Lund, Sweden. [Read more]

Sector Healthcare
Founded 2020
Employees 6
Stock Exchange Nasdaq Stockholm
Ticker Symbol NEWBRY
Full Company Profile

Financial Performance

In 2025, STO:NEWBRY's revenue was 31.57 million, a decrease of -14.27% compared to the previous year's 36.83 million. Losses were -23.88 million, 55.0% more than in 2024.

Financial Statements